Riskpilot← Back to searchSign inGet full accessMAXIPHARMA A/S
A/SActiveCVR 87375617Søren Nymarks Vej 25Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19793 employees
Revenue 2024
DKK 2,1M
+18% vs 2023
EBITDA margin
23.9%
-5% vs 2023
Equity ratio
81.4%
Financial strength
Net profit 2024
DKK 411K
+82% vs 2023
| Revenue | DKK 2,1M | +18% |
| EBITDA | DKK 514K | -5% |
| Net profit | DKK 411K | +82% |
| Total assets | DKK 4,9M | -6% |
| Equity | DKK 4M | +6% |
| Employees | 3 | — |
Legal name
MAXIPHARMA A/S
CVR number
87375617
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
20. maj 1979
Share capital
DKK 700.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af en direktør alene
Company purpose
Selskabets formål er at drive handel, herunder import og eksport samt agenturvirksomhed
Address
Søren Nymarks Vej 25
Phone
+4586292955
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.517 | 973 | 1.667 | 1.154 | 1.480 | 1.390 | 1.611 | 1.432 | 1.534 | 1.683 | 2.022 | 1.825 | 2.145 |
| Staff expenses | -900 | -815 | -915 | -901 | -875 | -861 | -865 | -857 | -889 | -971 | -1.045 | -1.287 | -1.631 |
| EBITDA | 618 | 158 | 751 | 254 | 605 | 530 | 746 | 575 | 645 | 711 | 978 | 538 | 514 |
| Depreciation & amort. | -16 | -17 | -17 | -12 | -20 | -61 | -67 | -67 | -65 | -57 | -8 | -0 | -0 |
| EBIT | 602 | 141 | 734 | 242 | 585 | 468 | 679 | 508 | 580 | 654 | 970 | 538 | 514 |
| Net financials | 345 | -422 | -69 | -481 | 137 | -52 | -810 | 485 | 377 | 613 | -630 | -248 | 14 |
| Profit before tax | 947 | -281 | 665 | -240 | 721 | 417 | -130 | 992 | 957 | 1.267 | 340 | 290 | 528 |
| Tax | 206 | -59 | 157 | -52 | 166 | 93 | -29 | 218 | 211 | 279 | 75 | 64 | 116 |
| Net profit | 740 | -222 | 508 | -188 | 556 | 323 | -102 | 774 | 746 | 988 | 265 | 226 | 411 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3.721 | 3.224 | 3.397 | 4.413 | 3.691 | 3.650 | 4.965 | 5.084 | 4.873 | 5.069 | 5.097 | 5.206 | 4.881 |
| Equity | 2.298 | 2.077 | 2.585 | 2.197 | 2.753 | 2.376 | 2.074 | 2.848 | 3.395 | 3.683 | 3.744 | 3.766 | 3.974 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 36 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.423 | 1.147 | 813 | 2.216 | 930 | 1.266 | 2.891 | 2.222 | 1.442 | 1.386 | 1.353 | 1.440 | 896 |
| Total debt | 1.423 | 1.147 | 813 | 2.216 | 930 | 1.266 | 2.891 | 2.236 | 1.479 | 1.386 | 1.353 | 1.440 | 896 |
EBITDA margin
23.9%
This company
15.8%
Market median
+51% vs market
20122024
Equity ratio
81.4%
This company
38.2%
Market median
+113% vs market
20122024
Return on equity
10.4%
This company
18.4%
Market median
+43% vs market
20122024
Net profit margin
19.2%
This company
8.1%
Market median
+137% vs market
20122024
Asset turnover
0.44×
This company
1.12×
Market median
-61% vs market
20122024
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Audit | 1979 | — | — | |
OJ Management | Management | 1979 | — | — |
JB Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
EM Audit | Audit | 1997 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1979 | — | — | |
| Board of Directors | 1979 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2010 | — | — | |
| Chairman | 2011 | — | — | |
| Board of Directors | 1979 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
AKTIESELSKABET SGJ | Company | 100.0% | 100.0% | 1992 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AKTIESELSKABET SGJ
MAXIPHARMA A/S Board members of MAXIPHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Revisionsfirmaet Langkilde Larsen, Århus | Audit | 0 companies |
| Ole Jensen | Management | 0 companies |
| Jesper Bjerre Jensen | Chief Executive Officer | 0 companies |
| Erling Mortensen | Audit | 0 companies |
| Anders Bøgh Andersen | Board of Directors | 0 companies |
| Elsebeth Aborg | Board of Directors | 0 companies |
| Benedikte Mailand Jensen | Chairman | 0 companies |
| Henrik Bencke | Board of Directors | 0 companies |
| Jens Indahl Henning | Chairman | 0 companies |
| Kurt Herman Okkerstrøm | Board of Directors | 0 companies |